Resumen
Cetuximab, which can be used in combination with other chemotherapies, is widely used as a standard of care treatment in the majority of advanced colorectal cancer (CRC) patients. However, the treatment of cetuximab-resistant CRC remains a major problem. The study was to assess the potential effects of radiotherapy on cetuximab-resistant CRC and explored the underlying mechanism. This review discussed a novel role of ACY1 in radiotherapy of cetuximab-resistant CRC, suggesting a possible target for cetuximab-resistant CRC treatment in the clinic.